Wedbush restated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $8.00 price objective on the stock. ELEV has been the topic of several other reports. JMP Securities restated a market outperform rating and set a $7.00 target price […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 4,630,000 shares, an increase of 28.3% from the February 29th total of 3,610,000 shares. Approximately 11.6% of the company’s shares are sold short. […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) – Investment analysts at HC Wainwright upped their Q1 2024 EPS estimates for Elevation Oncology in a research report issued to clients and investors on Thursday, March 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.20) per share for the quarter, up from […]
JMP Securities Reiterates Market Outperform Rating for Elevation Oncology (NASDAQ:ELEV) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Wedbush reiterated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. Wedbush also issued estimates for Elevation Oncology’s Q4 2023 earnings at ($0.26) EPS, FY2023 earnings at ($1.21) EPS, Q1 2024 […]